N/A N=54 Diagnosis and Treatment of Sleep Apnea in the Acute Exacerbation of Heart Failure
Sleep Apnea · Heart Failure
Primary: Left Ventricular Ejection Fraction Improvement — 4.5; -.3 percent change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=411 Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation
Heart Failure · Atrial Fibrillation
Primary: Composite of All-cause Mortality and Heart Failure Events — 50; 64 Participants
N/A N=34 Assessing the Hemodynamic Benefits of Cardiac Resynchronization Therapy in Children Following Open-Heart Surgery
Congenital Heart Defects
Primary: Cardiac Index — 3.39; 3.42; 3.23 L/min/m2
N/A N=19 High Intensity Interval Exercise in Diastolic Heart Failure
Diastolic Heart Failure
Primary: Left Ventricular Diastolic Dysfunction — 2.1; 2; 1.3; 2.2 DD grade
N/A N=72 mHealth for Self-care of Heart Failure in Uganda
Heart Failure
Primary: Self-Care for Heart Failure Index, Maintenance — 35; 85 score on a scale — p=<0.001
Phase 4 N=24 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit
Atrial Fibrillation
Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants
Phase 2 N=130 Thiamine and Acute Decompensated Heart Failure: Pilot Study
Heart Failure · Diabetes
Primary: Effect of Thiamine Supplementation on Dyspnea — 34; 32 mm
Phase 3 N=5,988 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
Heart Failure
Primary: Time to First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF) — 8.67; 6.86 Patients with event/100 pt-yrs at risk…
Phase 2 N=17 Dietary Nitrate for Heart Failure
Heart Failure · Hypertension, Pulmonary
Primary: Maximal Knee Extensor Power — 4.20; 4.74 W/kg — p=0.0153
Phase 3 N=2,743 A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines
Heart Failure
Primary: Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date — 249; 356…
N/A N=15 An Assessment of Dual Site Left Ventricular Endocardial Pacing
Atrial Fibrillation · Ventricular Tachycardia · Heart Failure
Primary: Acute Haemodynamic Response to Dual Left Ventricular Pacing — 3.7 % difference — p=<0.05
Phase 2 N=80 Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure
Heart Failure Acute · Heart Failure，Congestive · Heart Failure; With Decompensation
Primary: Dyspnea — 1264; 1650 mmxh — p=0.18
Phase 4 N=6 Treatment of Sleep Disordered Breathing In Acute Decompensated Heart Failure Patients
Heart Failure · Sleep Apnea Syndromes
Primary: Reduction in Episodic Oxygen Desaturation
N/A N=513 The Darlington Retrospective Outpatient Study
Heart Failure
Primary: All Cause Mortality — 163; 118 participants
N/A N=41 Curing Atrial Fibrillation in Heart Failure
Chronic Heart Failure · Atrial Fibrillation
Primary: Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)% — 2.8; 4.5 percentage of blood ejected in one beat